Jupiter Neurosciences, Inc. - Common Stock

Action · US48208B2034 · JUNS (XNAS)

Aperçu

Analyse alimentée par l’IA

Analyse fondamentale

Découvrez ce que disent vraiment les chiffres — avant le marché

Analyser maintenant

Sentiment des actualités

Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?

Analyser maintenant

Acheter / Conserver / Vendre

Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.

Analyser maintenant

Évaluation des risques

Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.

Analyser maintenant

Juste valeur

Cette action est-elle bon marché, correctement valorisée ou surévaluée ?

Analyser maintenant

Dernières analyses d’IA sur Jupiter Neurosciences, Inc. - Common Stock

Pas de cours

28.04.2026 22:04

Cours actuels de Jupiter Neurosciences, Inc. - Common Stock

Bourse	Ticker	Devise	Dernier échange	Cours	Variation journalière
NASDAQ	JUNS	USD	28.04.2026 22:04	0,36 USD	-0,003 USD -0,72 %
IEX	JUNS	USD	24.04.2026 15:03	0,39 USD	-

Flottant et Liquidité des Actions

Flottant Libre 50,52 %

Actions en Flottant 18,33 M

Actions en Circulation 36,28 M

Profil de l'entreprise pour Jupiter Neurosciences, Inc. - Common Stock Action

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.